6533b7d5fe1ef96bd12646db
RESEARCH PRODUCT
COVID-19 and Alzheimer’s Disease
Giulia BivonaTommaso PiccoliBruna Lo SassoCaterina Maria GambinoLuisa AgnelloConcetta ScazzoneMarcello CiaccioAnna Maria CiaccioRosaria Vincenza Gigliosubject
medicine.medical_specialtyNeurological injuryCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)neuroinflammation.DiseaseReviewneuroinflammationlcsh:RC321-57103 medical and health sciences0302 clinical medicineMedicineIntensive care medicinelcsh:Neurosciences. Biological psychiatry. NeuropsychiatryNeuroinflammation030304 developmental biologyNeurotropic virus0303 health sciencesneurodegenerative niseasebusiness.industrySARS-CoV-2General NeuroscienceHypogeusianervous systembiomarkersADAgeusiabiomarkermedicine.symptombusiness030217 neurology & neurosurgerydescription
The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is a neurotropic virus with a high neuroinvasive potential. Indeed, more than one-third of patients develop neurological symptoms, including confusion, headache, and hypogeusia/ageusia. However, long-term neurological consequences have received little interest compared to respiratory, cardiovascular, and renal manifestations. Several mechanisms have been proposed to explain the potential SARS-CoV-2 neurological injury that could lead to the development of neurodegenerative diseases, including Alzheimer’s Disease (AD). A mutualistic relationship between AD and COVID-19 seems to exist. On the one hand, COVID-19 patients seem to be more prone to developing AD. On the other hand, AD patients could be more susceptible to severe COVID-19. In this review, we sought to provide an overview on the relationship between AD and COVID-19, focusing on the potential role of biomarkers, which could represent precious tool for early identification of COVID-19 patients at high risk of developing AD.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2021-02-01 | Brain Sciences |